Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

NCT01877421 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

135

Enrollment

FED

Sponsor class

Conditions

Plaque
Gingivitis

Interventions

DRUG: 2 mg KSL-W
DRUG: 4 mg KSL-W
DRUG: 6 mg KSL-W
DRUG: 10 mg KSL-W
DRUG: 20 mg KSL-W
DRUG: 30 mg KSL-W
DRUG: 50 mg KSL-W
DRUG: 75 mg KSL-W
DRUG: 100 mg KSL-W
OTHER: Placebo

Sponsor

U.S. Army Medical Research and Development Command